EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Drug-induced Liver Injury from Intravenous Immunoglobulin for Prevention of Recurrent Gestational Alloimmune Liver Disease: A Clinical Catch-22

Jessica A Meyer iD, Jenna S Silverstein, Kristen M Thomas, Sara G Brubaker, Judith L Chervenak

American Journal of Perinatology Reports · 01.07.2024 · 14 (04) · e254-e258

DOI: 10.1055/a-2444-7155 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Perinatology Reports, erschienen am 01.07.2024. Verfasst von Jessica A Meyer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, NYU Grossman School of Medicine, New York, New York. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gestational alloimmune liver disease (GALD) is a rare autoimmune syndrome in which maternal antibodies lead to in utero fetal hepatocyte destruction, often presenting as neonatal liver failure and hemochromatosis. Antenatal intravenous immunoglobulin (IVIG) is generally accepted to be safe in pregnancy with demonstrable benefits for reducing GALD recurrence risk in subsequent pregnancies. Here we present a case of a 33-year-old woman with a prior neonatal demise due to GALD who received multiple prophylactic IVIG infusions in a subsequent twin pregnancy complicated by maternal jaundice and acute hepatitis. A liver biopsy demonstrated hepatocellular injury with bridging necrosis and cholestatic features consistent with drug-induced liver injury. This case demonstrates the importance of close clinical monitoring during IVIG therapy and the need for further research into alternative prophylaxis options for GALD. Key Points

Schlagwörter

Stichwörter der Autor:innen

antibodiesdrug-induced liver injurygestational alloimmune liver diseasehepatocellular damageintravenous immunoglobulinliverliver dysfunctionpregnancytransaminitis

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, NYU Grossman School of Medicine, New York, New York.
  • Department of Pathology, NYU Grossman School of Medicine, New York, New York.
  • Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Bellevue Hospital Center, New York, New York.
  • Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, NYU Langone Health, New York, New York.

ORCID-Profile: Jessica A Meyer

Zitieren

APA

Meyer, J. A., Silverstein, J. S., Thomas, K. M., Brubaker, S. G., & Chervenak, J. L. (2024). Drug-induced Liver Injury from Intravenous Immunoglobulin for Prevention of Recurrent Gestational Alloimmune Liver Disease: A Clinical Catch-22. American Journal of Perinatology Reports, 14(04), e254-e258. https://doi.org/10.1055/a-2444-7155

Vancouver

Meyer JA, Silverstein JS, Thomas KM, Brubaker SG, Chervenak JL. Drug-induced Liver Injury from Intravenous Immunoglobulin for Prevention of Recurrent Gestational Alloimmune Liver Disease: A Clinical Catch-22. American Journal of Perinatology Reports. 2024;14(04):e254-e258. doi:10.1055/a-2444-7155

BibTeX
@article{Meyer2024,
  author = {Meyer, Jessica A and Silverstein, Jenna S and Thomas, Kristen M and Brubaker, Sara G and Chervenak, Judith L},
  title = {Drug-induced Liver Injury from Intravenous Immunoglobulin for Prevention of Recurrent Gestational Alloimmune Liver Disease: A Clinical Catch-22},
  journal = {American Journal of Perinatology Reports},
  year = {2024},
  volume = {14},
  number = {04},
  pages = {e254--e258},
  doi = {10.1055/a-2444-7155}
}
Kostenlos starten →